Home > Press > Starpharma and Durex Sign Co-Development Agreement for VivaGel-Coated Condoms
Starpharma Holdings Ltd today announced the signing of an agreement with SSL International plc , owner of Durex(R), the world's leading condom brand.
Starpharma and Durex Sign Co-Development Agreement for VivaGel-Coated Condoms
SYDNEY, Australia | Posted on October 16th, 2007
The agreement, under which a commercial licence will be negotiated, sets out a co-development program for condoms with a VivaGel(R) coating. Undisclosed fees are payable to Starpharma under the co-development agreement, which also provides for the commencement of regulatory and market development activities by the two parties.
SSL is the world's largest manufacturer of condoms with approximately 30% share of the global market for branded condom sales, selling into over 100 countries around the world. Global condom retail sales in 2005 were approximately $3.2 billion(1)(1), with the top four companies representing as much as 70% of the market.
"We are delighted to be working with SSL, whom we believe will be an excellent co-development partner for VivaGel(R) as a condom coating," said Starpharma's Chief Executive Officer, Dr. Jackie Fairley. "In addition to SSL's unparalleled global commercial position and the strength of the Durex(R) brand, Starpharma also values the organisation's innovative approach, and its social-marketing program.
"Our development and commercialisation activities for VivaGel(R) are gathering momentum with this SSL agreement being the second of two unrelated condom coating agreements signed by Starpharma in the last three months," concluded Dr. Fairley.
VivaGel(R) has been shown to have potent contraceptive and microbicidal properties in animal studies, and is also under development as a stand-alone gel to prevent the transmission of STIs, including HIV and genital herpes.
(1)(1) "Condoms: A Global Strategic Business Report", March 2005, Global Industry Analysts Inc.
About Starpharma Holdings Limited
Starpharma Holdings Limited is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies, Inc. in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.
The Company's lead pharmaceutical development product is VivaGel(R) (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.
For more information, please click here
Tel: +61 2 9237 2800
Mob: +61 417 382 391
Dr. Jackie Fairley
Chief Executive Officer
+61 3 8532 2704
+61 3 8532 2702
Copyright © PR Newswire Association LLC.
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
HZO Teams With Deutsche Telekom to Unveil the Waterproof Tolino Vision 2 eReader: The New HZO Protected eReader Ushers in a New Era of Waterproof Electronics, Providing a Seamless User Experience Without the Risk of Using Port Doors and Mechanical Seals October 10th, 2014
7th Nanotechnology Festival, Exhibition Kicks Off Work in Iran October 7th, 2014
Next-Gen Luxury RV From Global Caravan Technologies Will Offer MagicView Roof and Windshield Using SPD-SmartGlass Technology From Research Frontiers: Recreational Vehicle Manufacturer Global Caravan Technologies (GCT) Features 28 Square Feet of MagicView™ SPD-SmartGlass September 17th, 2014
Fonon at Cutting-Edge of 3D Military Printing: Live-Combat Scenarios Could See a Decisive Advantage with 3D Printing September 15th, 2014
NanoTechnology for Defense (NT4D) October 22nd, 2014
Mechanism behind nature's sparkles revealed October 22nd, 2014
TARA Biosystems and Harris & Harris Group Form Company to Improve Safety and Efficacy of New Therapies October 22nd, 2014
Researchers patent a nanofluid that improves heat conductivity October 22nd, 2014
European Commission opens the gate towards the implementation of Nanomedicine Translation Hub October 16th, 2014
IRLYNX and CEA-Leti to Streamline New CMOS-based Infrared Sensing Modules Dedicated to Human-activities Characterization October 15th, 2014
New VDMA Association "Electronics, Micro and Nano Technologies" founded: Inaugural Meeting in Frankfurt/Main, Germany October 15th, 2014
VDMA photonics steering committee with new members stronger than ever October 14th, 2014
Brookhaven Lab Launches Computational Science Initiative:Leveraging computational science expertise and investments across the Laboratory to tackle "big data" challenges October 22nd, 2014
Detecting Cancer Earlier is Goal of Rutgers-Developed Medical Imaging Technology: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions October 21st, 2014
Nitrogen Doped Graphene Characterized by Iranian, Russian, German Scientists October 21st, 2014
Crystallizing the DNA nanotechnology dream: Scientists have designed the first large DNA crystals with precisely prescribed depths and complex 3D features, which could create revolutionary nanodevices October 20th, 2014